Affinity Investment Advisors, LLC Ironwood Pharmaceuticals Inc Transaction History

Affinity Investment Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$10.1 - $11.6 $112,726 - $129,467	-11,161 Reduced 18.03%	50,733 $539,000
Q4 2022 Feb 08, 2023	BUY	$9.9 - $12.43 $4,732 - $5,941	478 Added 0.78%	61,894 $766,000
Q2 2022 Jul 27, 2022	SELL	$11.05 - $12.72 $27,514 - $31,672	-2,490 Reduced 3.9%	61,416 $708,000
Q1 2022 May 05, 2022	SELL	$10.61 - $12.88 $26,100 - $31,684	-2,460 Reduced 3.71%	63,906 $804,000
Q4 2021 Feb 04, 2022	BUY	$10.86 - $13.95 $3,887 - $4,994	358 Added 0.54%	66,366 $774,000
Q3 2021 Nov 08, 2021	BUY	$11.92 - $13.92 $369 - $431	31 Added 0.05%	66,008 $862,000
Q4 2020 Feb 12, 2021	BUY	$9.05 - $12.2 $597,091 - $804,919	65,977 New	65,977 $751,000

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $562M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Affinity Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Investment Advisors, LLC with notifications on news.